IPK and Euroscreen Form Alliance for GPCR Drug Discovery
News Feb 28, 2006
The development at the Institute Pasteur Korea of a visual-based High Throughput Screening platform is designed to offer opportunities for the identification of drug candidates activating receptor internalization while Euroscreen’s receptor cell lines and GPCR library compounds will provide the initial direction and components for this drug discovery collaboration.
This partnership takes thus advantage of both IPK expertise in the image analysis and HCS fields and Euroscreen competence in GPCR biology and Chemistry tools.
"We are delighted to be working with Euroscreen s.a. on this GPCR Drug Discovery project," commented Dr. Thierry Christophe, Head of Screening Technologies and Pharmacology at Institute Pasteur Korea.
"This partnership highlights the increasing interest in visual-based screening technologies to identify more selective drug candidates. It validates the screening approach we develop at IPK."
"Collaborating with one of the World’s leaders in the GPCR science sector signifies an important step in materialising IPK’s innovative approach. We are enthusiastic to have found a highly competent partner in Euroscreen, to take HCS screening to the next level," added Dr. Ulf Nehrbass, Director and CEO of IPK.
"This should provide our companies with a rapid, joint opportunity to develop drug candidates which selectively cause the internalization of GPCRs for their therapeutic action in vivo," said Dr. François Roman, the Head of Drug Development R&D at Euroscreen.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019